ENTITY
Akeso

Akeso (9926 HK)

369
Analysis
Health Care • China
Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.
more
bullish•Hang Seng Index
•05 Jul 2026 06:22

Hong Kong Single Stock Options Weekly June 29–July 03: Semi Rotation Drives a Shift in Tone

Semi rotation, firmer Hong Kong equities, elevated single stock implied vols, and broad Health Care strength shaped the week in Hong Kong options.

Logo
John Ley
151 Views
Share
•01 Jul 2026 14:50

MS-China Index Earning Revision (Jun): XPENG, COSCO SHIP ENGY, MEITUAN, TENCENT, PDD, GCL TECHNOLOGY

We analyzed MS-China's consensus for Jun 2026 and highlighted changes of EPS in XPENG, COSCO SHIP ENGY, MEITUAN, TENCENT, PDD, GCL TECHNOLOGY, Full...

Logo
123 Views
Share
•29 Jun 2026 14:10

HSCEI Index Earning Revision (Jun): HAIER SMARTHOME, BOC, AKESO, Kuaishou, XPENG, ZIJIN MINING

We analyzed HSCEI's consensus for Jun 2026 and highlighted changes of EPS in HAIER SMARTHOME, BOC, AKESO, Kuaishou, XPENG, ZIJIN MINING, MEITUAN,...

Logo
125 Views
Share
bullish•Pop Mart
•22 Jun 2026 04:42

Pop Mart, Trip.com, Geely Auto, and More: Weekly Options Start Trading on 15 June

Today, HKEX launches weekly trading in options on Geely (175 HK), Li Auto (2015 HK), XPeng (9868 HK), NetEase (9999 HK), Sun Hung Kai Properties...

Logo
156 Views
Share
•07 Jun 2026 11:10

HSCEI June 2026 Index Rebalance: Pre-Implementation Update

HSCEI enters the implementation phase on 8 Jun 2026. We update stock pre-implementation performance and discuss implementation trades.

Logo
136 Views
Share
x